A therapeutic use of CB2 as anti-obesity target might presume a related chronic neuronal activation, that, in turn, increasing excitatory synaptic transmission, should facilitate the peripheral anti-obesity effects without exerting remarkable psychotropic activity. This evidence concerns the gene CNR2 and obesity due to melanocortin 4 receptor deficiency.